Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-25

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Furosemide is an old drug that has been used frequently in the postoperative period of kidney transplantation, aiming to achieve adequate urine output. There is no previous study that directly evaluate the urine response to standardized dose of furosemide in the postoperative period. The objective is to measure the urine output after standardized dose of furosemide is delivered, as a biomarker to predict the graft function in perioperative period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Fibroblast Growth Factor 23 (FGF-23) and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients

NCT00903578

Kidney Transplantation

UNKNOWN

Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations

NCT06367205

Delayed Graft Function End Stage Renal Disease Kidney Transplantation

RECRUITING NA

To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors

NCT03676361

Kidney Damage

WITHDRAWN PHASE4

The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients

NCT07275632

Delayed Graft Function Kidney Transplantation

RECRUITING PHASE1/PHASE2

Diagnosis of Acute Rejection in Renal Transplant Patients by Urine Mass Spectrometry

NCT01315067

Rejection of Renal Transplant

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Function Kidney Transplant; Complications Delayed Graft Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Furosemide

Single dose of furosemide 1.5 mg/kg intravenously will be given to all participants at 3 hours post-reperfusion of kidney allograft.

Urine output will be recorded hourly for 6 hours.

Group Type EXPERIMENTAL

Furosemide Injection

Intervention Type DRUG

Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Furosemide Injection

Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Deceased donor kidney transplantation at KCMH
* informed consent is accepted

Exclusion Criteria

* Known allergy to furosemide
* Surgical complication of allograft
* Urgently needed for dialysis (refractory hypervolemia, uremic symptoms, and hyperkalemia)

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No